The U.S. Immigration and Customs Enforcement awarded an indefinite delivery contract to Abbott Rapid DX North America LLC for rapid molecular COVID-19 testing services. Under the contract vehicle, ICE issued three firm fixed price delivery orders totaling $11.8 million to Abbott for Rapid Molecular ID NOW COVID-19 test kits, control kits, and instruments. The test kits and instruments will enable ICE Health Service Corps and Enforcement and Removal Operations to conduct on-site point-of-care COVID-19 testing at their detention and processing centers through December 2022. ICE requires expanded testing capacity to support surge requirements and the safe operation of its facilities amidst the ongoing coronavirus pandemic. Abbott will provide the test kits and instruments on a delivery order basis for use at locations across the continental United States. No set aside provisions or subcontracting arrangements were outlined in the contract documentation provided.
The indefinite delivery contract establishes Abbott as the prime contractor eligible to fulfill COVID-19 molecular testing requirements on behalf of ICE through task order awards. The first delivery order in March 2021 was valued at $5.9 million for supplies to be delivered to Lockhart, Florida. Two additional orders in January 2021 totaled $5.9 million to provide test kits and instruments to ICE sites in Washington, D.C. Taken together, the orders enable ICE to access Abbott's rapid COVID-19 testing technology on an as-needed basis to help mitigate spread of the virus within its detention and law enforcement operations.
Generated 1/4/24, 9:30 PM